We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04886739
Recruitment Status : Completed
First Posted : May 14, 2021
Last Update Posted : August 9, 2022
Sponsor:
Collaborator:
ethica Clinical Research Inc.
Information provided by (Responsible Party):
CAGE Bio Inc.

Brief Summary:

This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12.

Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.


Condition or disease Intervention/treatment Phase
Rosacea Drug: CGB-400 Drug: Vehicle Gel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Safety and Effectiveness of CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea: A Randomized, Double-Blind, Vehicle-Controlled Proof of Concept Study
Actual Study Start Date : May 7, 2021
Actual Primary Completion Date : December 22, 2021
Actual Study Completion Date : December 22, 2021

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Rosacea
MedlinePlus related topics: Rosacea

Arm Intervention/treatment
Experimental: CGB-400 Topical Gel
Topical administration twice daily for 12 weeks
Drug: CGB-400
Topical gel

Placebo Comparator: Vehicle Gel
Topical administration twice daily for 12 weeks
Drug: Vehicle Gel
Topical gel




Primary Outcome Measures :
  1. Inflammatory Lesion Count [ Time Frame: Week 12 ]
    Numerical count of inflammatory lesions (pustules and papules)

  2. Investigator Global Assessment (IGA) [ Time Frame: Week 12 ]
    • 0 - Clear; No inflammatory lesions present; at most mild erythema
    • 1 - Almost clear; Very mild erythema present. Very few small papules/pustules
    • 2 - Mild; Mild erythema. Several small papules/pustules
    • 3 - Moderate; Moderate erythema. Several small or large papules/pustules
    • 4 - Severe; Severe erythema. Numerous small and/or large papules/pustules


Secondary Outcome Measures :
  1. Inflammatory Lesion Count [ Time Frame: Weeks 2, 4, and 8 ]
    Numerical count of inflammatory lesions (pustules and papules)

  2. Investigator Global Assessment (IGA) [ Time Frame: Weeks 2, 4, and 8 ]
    • 0 - Clear; No inflammatory lesions present; at most mild erythema
    • 1 - Almost clear; Very mild erythema present. Very few small papules/pustules
    • 2 - Mild; Mild erythema. Several small papules/pustules
    • 3 - Moderate; Moderate erythema. Several small or large papules/pustules
    • 4 - Severe; Severe erythema. Numerous small and/or large papules/pustules

  3. Rosacea Quality of Life (RosaQoL) Questionnaire [ Time Frame: Week 12 ]
    Patient Reported Outcome



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Outpatient, male or female of any race, 18 years of age or older. Female subjects of childbearing potential must have a negative UPT at Baseline and practice a reliable method of contraception throughout the study.
  • Clinical diagnosis of papulopustular facial rosacea.
  • Investigator Global Assessment (IGA) score of 3 or 4 (i.e., moderate or severe).
  • Facial inflammatory lesion count (i.e., papules and pustules) of ≥15 and ≤50 (excluding lesions involving the eyes and scalp) with ≤2 nodules.
  • Willing to forego any other topical or non-topical treatment, cosmetic, OTC, or prescription on the study areas during treatment (other than sun protection or the study specified face wash and moisturizer).
  • Willing to use the provided skincare regimen (e.g., face wash, moisturizer) during the study.
  • In general good health as determined by medical history and physical examination at the time of screening (Investigator discretion).
  • Sign the IRB-approved ICF (which includes HIPAA) prior to any study-related procedures being performed.

Exclusion Criteria:

  • Female subjects that are pregnant, breast-feeding, or of childbearing potential and not practicing reliable birth control (as specified in Section 5.1).
  • Known hypersensitivity or previous allergic reaction to any constituent of the Investigational Product (i.e., essential oils, fragrance, choline, phosphatidylcholine, propylene glycol, limonene, cellulose).
  • Any transient flushing syndrome.
  • Particular forms of rosacea (ocular rosacea, rosacea conglobata, rosacea fulminans, isolated rhinophyma, granulomatous rosacea, phymatous rosacea, plaque-type rosacea lesions isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
  • Papulopustular rosacea that had required systemic treatment within the past 12 months.
  • Facial skin conditions that can interfere with reliable rosacea assessments (e.g., keloids, hypertrophic scarring, dense telangiectasia, plaque-like facial edema, recent facial surgery, etc.).
  • Facial dermatoses that may be confounded with papulopustular rosacea (e.g., perioral dermatitis, facial keratosis pilaris, seborrheic dermatitis, acne fulminans, etc.).
  • History or presence of a skin condition/disease that is located in the treatment area(s) and might interfere with the diagnosis or evaluation of study parameters (i.e., atopic dermatitis, psoriasis, significant actinic damage, vitiligo, open wounds, infection, etc.).
  • Basal cell carcinoma within 6 months of Visit 1.
  • Uncontrolled systemic disease.
  • Foreseen unprotected and intense/excessive UV exposure during the course of the study.
  • Use of prohibited concomitant medications/procedures, as specified below in Table 1, during the study or within the defined washout periods.
  • Scheduled or planned surgical procedures during the course of the study.
  • Unable or unwilling to comply with any of the study requirements.
  • Medical or psychiatric conditions, or a personal situation, that may increase the risk associated with study participation or may interfere with interpretation of study results or subject compliance and, in the opinion of the PI, makes the subject inappropriate for study entry.
  • Clinically significant alcohol or drug abuse, or history of poor cooperation or unreliability.
  • Exposure to any other investigational drug/device within 30 days prior to study entry

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04886739


Locations
Layout table for location information
United States, California
Cage Bio Investigative Site 1
Fremont, California, United States, 94538
Sponsors and Collaborators
CAGE Bio Inc.
ethica Clinical Research Inc.
Layout table for additonal information
Responsible Party: CAGE Bio Inc.
ClinicalTrials.gov Identifier: NCT04886739    
Other Study ID Numbers: CGB-400-002
First Posted: May 14, 2021    Key Record Dates
Last Update Posted: August 9, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rosacea
Skin Diseases